Table 2. Comparative effectiveness and safety of adalimumab vs. infliximab in biologic-naïve patients with ulcerative colitis, using propensity score-matched analysis.
| Adalimumab (N=104) | Infliximab (N=131-171)+ | Adalimumab vs. infliximab | ||||
|---|---|---|---|---|---|---|
| Number of events | Incidence rate, per 100-py (95% CI) | Number of events | Incidence rate, per 100-py (95% CI) | HR (95% CI) | p-value | |
| All-cause hospitalization | 36 | 91.5 (66.0-126.9) | 49 | 37.4 (28.3-49.5) | 1.84 (1.18-2.85) | 0.007 |
| UC-related hospitalization | 20 | 46.7 (30.1-72.3) | 28 | 19.3 (13.4-28.0) | 1.71 (0.95-3.07) | 0.07 |
| Major abdominal surgery | 10 | 20.7 (11.1-38.4) | 18 | 11.4 (7.2-18.1) | 1.35 (0.62-2.94) | 0.45 |
| New steroid use | 5 | 18.6 (7.7-44.6) | 20 | 22.6 (14.6-35.0) | 0.66 (0.24-1.79) | 0.41 |
| Serious infection | 5 | 10.3 (4.3-24.7) | 3 | 1.9 (0.6-5.8) | 5.11 (1.20-21.80) | 0.03 |
+
Depending on outcome, the number of matched infliximab-treated patients with UC were 131-171
[Abbreviations: CI-confidence interval, HR-hazard ratio, py-person-years, UC-ulcerative colitis]